A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Boehringer Ingelheim
Corcept Therapeutics
Teclison Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Exelixis
Eli Lilly and Company
Novartis
Orano Med LLC
Amgen
BioNTech SE
Merck Sharp & Dohme LLC
Travera Inc
RayzeBio, Inc.
Molecular Partners AG
Novartis
ITM Solucin GmbH
Novo Nordisk A/S
Turning Point Therapeutics, Inc.
Ipsen
Moonlight Bio, Inc
RayzeBio, Inc.
Boston Scientific Corporation
Hoffmann-La Roche